ID   LP [Human diffuse large B-cell lymphoma]
AC   CVCL_ZC22
DR   Wikidata; Q98126932
RX   PubMed=16099873;
RX   PubMed=20889926;
RX   PubMed=29416618;
RX   PubMed=29666304;
RX   PubMed=30165192;
DI   NCIt; C36081; Diffuse large B-cell lymphoma activated B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 21-03-23; Version: 3
//
RX   PubMed=16099873; DOI=10.1182/blood-2005-03-1167; PMCID=PMC1895110;
RA   Pham L.V., Tamayo A.T., Yoshimura L.C., Lin-Lee Y.-C., Ford R.J. Jr.;
RT   "Constitutive NF-kappaB and NFAT activation in aggressive B-cell
RT   lymphomas synergistically activates the CD154 gene and maintains
RT   lymphoma cell survival.";
RL   Blood 106:3940-3947(2005).
//
RX   PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744;
RA   Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E.,
RA   Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.;
RT   "Constitutive BR3 receptor signaling in diffuse, large B-cell
RT   lymphomas stabilizes nuclear factor-kappaB-inducing kinase while
RT   activating both canonical and alternative nuclear factor-kappaB
RT   pathways.";
RL   Blood 117:200-210(2011).
//
RX   PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470;
RA   Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C.,
RA   Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr.,
RA   Pham L.V.;
RT   "Preclinical efficacy and biological effects of the oral proteasome
RT   inhibitor ixazomib in diffuse large B-cell lymphoma.";
RL   Oncotarget 9:346-360(2018).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=30165192; DOI=10.1016/j.canlet.2018.08.020;
RA   Qu C.-J., Kunkalla K., Vaghefi A., Frederiksen J.K., Liu Y.-D.,
RA   Chapman J.R., Blonska M., Bernal-Mizrachi L., Alderuccio J.P.,
RA   Lossos I.S., Landgraf R., Vega-Vazquez F.;
RT   "Smoothened stabilizes and protects TRAF6 from degradation: a novel
RT   non-canonical role of smoothened with implications in lymphoma
RT   biology.";
RL   Cancer Lett. 436:149-158(2018).
//